All In Biotech

Drug Trial Radar · NCT06281678

A Study of IBI363 in Subjects with Advanced Solid Malignancies

A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

178

Planned (sponsor's estimate)

Start

Apr 8, 2024

Primary completion

Mar 1, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

Conditions

  • Melanoma
  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Renal Cell Cancer

Interventions

  • IBI363Drug

    IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks. Subjects will receive study medication until disease progression, toxicity intolerance, withdrawal of consent, the duration of treatment reaches 24 months, or any other reason that requires discontinuation of the study treatment, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: up to 2 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco (UCSF)

    San Francisco, California · Recruiting

  • Ocala Oncology Center

    Ocala, Florida · Recruiting

  • BRCR Medical Center

    Plantation, Florida · Recruiting

  • University of Kansas Medical Center (KUMC)

    Fairway, Kansas · Recruiting

  • Michigan Hematology & Oncology Consultants - MedOnc Dearborn

    Dearborn, Michigan · Recruiting

  • Michigan Hematology & Oncology Consultants - MedOnc Troy

    Troy, Michigan · Recruiting

  • MD Anderson Cancer Center-University of Texas

    Houston, Texas · Recruiting

  • Oncology Consultants P.A.

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.